In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J cuts Nizoral to focus on core lines

This article is powered by OTC Bulletin & The Rose Sheet

Executive Summary

Johnson & Johnson (J&J) is offloading the rights to the Nizoral dandruff treatment in three separate deals as part of its strategy to divest non-core assets and focus on its larger Consumer brands.


Related Content

German OTC Marketing Round-Up, May: Stada, Pohl Boskamp, Bene And Almirall
J&J Names New EMEA Chief To Drive Consumer Growth





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts